头孢丙烯与头孢克洛随机对照治疗下呼吸道感染患者的临床评价

目的　评价头孢丙烯与头孢克洛随机对照治疗下呼吸道感染的疗效和安全性。方法　轻、中度下呼吸道感染患者 12 0例随机分成两组 ,头孢丙烯组 6 2例予头孢丙烯 5 0 0mg ,口服 ,2次 /d ;头孢克洛组 5 8例予头孢克洛5 0 0mg ,口服 ,3次 /d。两组均以 7～ 14天为 1个疗程。结果　头孢丙烯组与头孢克洛组的临床有效率分别为 91.9%与 89.7% (P >0 .0 5 ) ,细菌消除率为 89.8%与 88.9% (P >0 .0 5 ) ,两组均无明显不良反应。结论　头孢丙烯可作为治疗轻、中度下呼吸道感染有效和安全的抗生素

Randomized controlled clinical trial of cefprozil vs cefaclor in treatment of lower respiratory tract infection

Objective To evaluate the efficacy and safety of cefprozil in the treatment of lower respiratory tract infections. Methods One hundred and twenty patients with mild to moderate lower respiratory tract infection were divided into two groups. Sixty two patients were treated with cefprozil 500 mg, orally,twice a day, Fifty eight patients were treated with cefaclor 500 mg,orally,threetimes a day. In both groups 7-14 d was a treatment course. Results The total clinical effective rates of cefprozil and cefaclor were 91.9 % and 89.7 % ( P > 0.05 ), respectively. The bacterial clearance rates were 89.8 % and 88.9 % ( P > 0.05 ), respectively. Both groups showed no obvious adverse reactions. Conclusion Cefprozil is a safe and potent antibacterial agent in treating mild to moderate lower respiratory tract infection.